Cargando…

Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study

The introduction of the so-called immune checkpoint inhibitors (ICIs) substantially changed the history of cancer therapy. On the other hand, they can induce the development of rheumatic immune-related adverse events (Rh-irAEs). In the scenario of a joint oncology/rheumatology outpatient clinic, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceccarelli, Fulvia, Natalucci, Francesco, Picciariello, Licia, Olivieri, Giulio, Cirillo, Alessio, Gelibter, Alain, Picone, Vincenzo, Botticelli, Andrea, Conti, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141051/ https://www.ncbi.nlm.nih.gov/pubmed/37109406 http://dx.doi.org/10.3390/life13040877

Ejemplares similares

Application of Machine Learning Models in Systemic Lupus Erythematosus
por: Ceccarelli, Fulvia, et al.
Publicado: (2023)

Development of Systemic Autoimmune Diseases in Healthy Subjects Persistently Positive for Antiphospholipid Antibodies: Long-Term Follow-Up Study
por: Ceccarelli, Fulvia, et al.
Publicado: (2022)

The Impacts of the Clinical and Genetic Factors on Chronic Damage in Caucasian Systemic Lupus Erythematosus Patients
por: Ceccarelli, Fulvia, et al.
Publicado: (2022)

Systemic Lupus Erythematosus before and after COVID-19 Lockdown: How the Perception of Disease Changes through the Lenses of Narrative Medicine
por: Ceccarelli, Fulvia, et al.
Publicado: (2021)

Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity
por: Ceccarelli, Fulvia, et al.
Publicado: (2023)

IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137(+)T-cells
por: Ugolini, Alessio, et al.
Publicado: (2020)

Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario
por: Trevisani, Francesco, et al.
Publicado: (2022)

Staphylococcus aureus Nasal Carriage and Autoimmune Diseases: From Pathogenic Mechanisms to Disease Susceptibility and Phenotype
por: Ceccarelli, Fulvia, et al.
Publicado: (2019)

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2019)

Correction: Biomarkers of erosive arthritis in systemic lupus erythematosus: Application of machine learning models
por: Ceccarelli, Fulvia, et al.
Publicado: (2019)

Biomarkers of erosive arthritis in systemic lupus erythematosus: Application of machine learning models
por: Ceccarelli, Fulvia, et al.
Publicado: (2018)

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2020)

Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus
por: Ceccarelli, Fulvia, et al.
Publicado: (2018)

PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort
por: Santini, Daniele, et al.
Publicado: (2021)

An observational multicentre study on the efficacy and safety of assisted reproductive technologies in women with rheumatic diseases
por: Reggia, Rossella, et al.
Publicado: (2019)

Circulating CD137(+) T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2022)

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
por: Cortellini, Alessio, et al.
Publicado: (2019)

The Impact of Caffeine Intake on Patients with Systemic Lupus Erythematosus: Protect Yourself, Drink More Coffee!
por: Orefice, Valeria, et al.
Publicado: (2020)

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
por: Botticelli, Andrea, et al.
Publicado: (2021)

Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases
por: Pecani, Arbi, et al.
Publicado: (2016)

Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors
por: Melissaropoulos, Konstantinos, et al.
Publicado: (2020)

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study
por: Cortellini, Alessio, et al.
Publicado: (2020)

Erratum to: Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases
por: Pecani, Arbi, et al.
Publicado: (2016)

Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
por: Spinelli, Francesca Romana, et al.
Publicado: (2023)

Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium
por: Ceccarelli, Fulvia, et al.
Publicado: (2022)

Descriptive Kinematic Analysis of the Potentially Tragic Accident at the 2020 Austrian MotoGP Grand Prix Using Low-Cost Instruments: A Brief Report
por: Gervasi, Marco, et al.
Publicado: (2020)

The role of opioids in cancer response to immunotherapy
por: Botticelli, Andrea, et al.
Publicado: (2021)

Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
por: Ceeraz, Sabrina, et al.
Publicado: (2014)

Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy
por: Kostine, Marie, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
por: Lee, Kyung-Ann, et al.
Publicado: (2019)

Autophagy in Rheumatic Diseases: Role in the Pathogenesis and Therapeutic Approaches
por: Celia, Alessandra Ida, et al.
Publicado: (2022)

Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach
por: Botticelli, Andrea, et al.
Publicado: (2023)

The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study
por: Botticelli, Andrea, et al.
Publicado: (2021)

Management of mycophenolate mofetil-induced acne in patients with Systemic Lupus Erythematosus: report of four cases and review of the literature
por: Perricone, Carlo, et al.
Publicado: (2018)

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
por: Xiao, Yan, et al.
Publicado: (2020)

Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective
por: Steven, Neil M, et al.
Publicado: (2019)

Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Shen, Pan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4gb6k31l69tvbf472kga6ti5m3